Cancer vaccines: Current directions and perspectives in prostate cancer

Current Opinion in Molecular Therapeutics

Volumn 11, Issue 1, 2009, Pages 31-36

  Mohebtash, M ^a   Gulley, J L ^a   Madan, R A ^a   Ferrara, T ^a   Arlen, P M ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Cancer vaccine; Immune response; Prostrate cancer; Tumor associated antigen

Indexed keywords

ANDROGEN; CANCER VACCINE; CYCLOPHOSPHAMIDE; CYTOKINE; DENDRITIC CELL VACCINE; DOCETAXEL; DOXORUBICIN; FLUTAMIDE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; IPILIMUMAB; MONOCLONAL ANTIBODY; NILUTAMIDE; ONYVAX P; PLACEBO; PREDNISONE; PROSTVAC VF; PROVENGE; PSA TRICOM; RECOMBINANT VACCINE; TUMOR ANTIGEN; TUMOR CELL VACCINE; UNCLASSIFIED DRUG; VIRUS VACCINE;

ALLOPATHY; ANDROGEN DEPRIVATION THERAPY; CANCER CELL; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CLINICAL TRIAL; DRUG DOSE ESCALATION; HUMAN; IMMUNE RESPONSE; IMMUNOSTIMULATION; MEDICAL RESEARCH; NONHUMAN; POXVIRUS; PROSTATE CANCER; REVIEW; THERAPY EFFECT;

ANIMALS; CANCER VACCINES; HUMANS; MALE; PROSTATIC NEOPLASMS;

EID: 58849156046     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (57)

1. Schlom J, Arlen PM, Gulley JL: Cancer vaccines: Moving beyond current paradigms. Clin Cancer Res (2007) 13(13):3776-3782. • This comprehensive review describes the changing paradigms in cancer vaccines, with a focus on prostate cancer.
2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ: Cancer statistics, 2008. CA Cancer J Clin (2008) 58(2):71-96.
3. Coffey DS, Isaacs JT: Prostate tumor biology and cell kinetics - theory. Urology (1981) 17(Suppl 3):40-53.
4. Matzinger P. The danger model: A renewed sense of self. Science (2002) 296(5566):301-305.
5. Fong L, Small EJ: Immunotherapy for prostate cancer. Semin Oncol (2003) 30(5):649-658.
6. Rhodes DR, Barrette TR, Rubin MA, Ghosh D, Chinnaiyan AM: Meta-analysis of microarrays: Interstudy validation of gene expression profiles reveals pathway dysregulation in prostate cancer. Cancer Res (2002) 62(15):4427-4433.
7. Sharifi N, Gulley JL, Dahut WL: Androgen deprivation therapy for prostate cancer. J Am Med Assoc (2005) 294(2):238-244.
8. Arlen PM, Gulley JL, Todd N, Lieberman R, Steinberg SM, Morin S, Bastian A, Marte J, Tsang KY, Beetham P, Grosenbach DW et al: Antiandrogen, vaccine and combination therapy in patients with nonmetastatic hormone refractory prostate cancer. J Urol (2005) 174(2):539-546. • This clinical trial suggested that survival improved in patients with prostate cancer who received a combination of anti-androgen therapy and vaccine.
9. Drake CG, Doody AD, Mihalyo MA, Huang CT, Kelleher E, Ravi S, Hipkiss EL, Flies DB, Kennedy EP, Long M, McGary PW et al: Androgen ablation mitigates tolerance to a prostate/prostate cancer-restricted antigen. Cancer Cell (2005) 7(3):239-249.
10. Sutherland JS, Goldberg GL, Hammett MV, Uldrich AP, Berzins SP, Heng TS, Blazar BR, Millar JL, Malin MA, Chidgey AP, Boyd RL: Activation of thymic regeneration in mice and humans following androgen blockade. J Immunol (2005) 175(4):2741-2753.
11. Mercader M, Bodner BK, Moser MT, Kwon PS, Park ES, Manecke RG, Ellis TM, Wojcik EM, Yang D, Flanigan RC, Waters WB et al: T cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancer. Proc Natl Acad Sci USA (2001) 98(25):14565-14570.
12. Nesslinger NJ, Sahota RA, Stone B, Johnson K, Chima N, King C, Rasmussen D, Bishop D, Rennie PS, Gleave M, Blood P et al: Standard treatments induce antigen-specific immune responses in prostate cancer. Clin Cancer Res (2007) 13(5): 1493-1502.
13. Beer TM, Bernstein GT, Corman JM, Glode ML, Hall S, Poll WL, Schellhammer PF, Xu Y, Yu L, Frohlich MW: Randomized trial of active cellular immunotherapy with sipuleucel-T in androgen dependent prostate cancer (ADPC). J Clin Oncol (2007) 25(18S):5059.
14. Madan RA, Gulley JL, Schlom J, Steinberg SM, Liewehr DJ, Dahut WL, Arlen PM: Analysis of overall survival in patients with nonmetastatic castration-resistant prostate cancer treated with vaccine, nilutamide, and combination therapy. Clin Cancer Res (2008) 14(14):4526-4531.
15. Clinical trials for prostate cancer. Phase II randomized pilot study of flutamide with versus without vaccine therapy comprising recombinant vaccinia prostate-specific antigen vaccine and recombinant fowlpox prostate-specific antigen vaccine in patients with androgen-insensitive, nonmetastatic prostate cancer. National Cancer Institute, Bethesda, MD, USA (2008). www.cancer.gov/search/ViewClinicalTrials.aspx?cdrid=535593&version= HealthProfessional&protocolsearchid=5433231
16. Clinical trials for prostate cancer. Phase II randomized study of ONY-P1 vaccine in patients with stage D0 prostate cancer. National Cancer Institute, Bethesda, MD, USA (2008). www.cancer.gov/search/ ViewClinicalTrials.aspx?cdrid=559937&version=HealthProfessional& protocolsearchid=5433231
17. Garnett CT, Palena C, Chakraborty M, Tsang KY, Schlom J, Hodge JW: Sublethal irradiation of human tumor cells modulates phenotype resulting in enhanced killing by cytotoxic T lymphocytes. Cancer Res (2004) 64(21):7985-7994.
18. Friedman EJ: Immune modulation by ionizing radiation and its implications for cancer immunotherapy. Curr Pharm Des (2002) 8(19):1765-1780.
19. Chakraborty M, Abrams SI, Camphausen K, Liu K, Scott T, Coleman CN, Hodge JW: Irradiation of tumor cells up-regulates Fas and enhances CTL lytic activity and CTL adoptive immunotherapy. J Immunol (2003) 170(12):6338-6347.
20. Hodge JW, Guha C, Neefjes J, Gulley JL: Synergizing radiation therapy and immunotherapy for curing incurable cancers. Opportunities and challenges. Oncology (2008) 22(9):1064-1070.
21. Harris TJ, Hipkiss EL, Borzillary S, Wada S, Grosso JF, Yen HR, Getnet D, Bruno TC, Goldberg MV, Pardoll DM, DeWeese TL et al: Radiotherapy augments the immune response to prostate cancer in a time-dependent manner. Prostate (2008) 68(12):1319-1329.
22. Gulley JL, Arlen PM, Bastian A, Morin S, Marte J, Beetham P, Tsang KY, Yokokawa J, Hodge JW, Ménard C, Camphausen K et al: Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer. Clin Cancer Res (2005) 11(9):3353-3362. • A significant immune response in patients with localized prostate cancer who received a combination of vaccine and radiotherapy was observed.
23. Terando A, Mulé JJ: On combining antineoplastic drugs with tumor vaccines. Cancer Immunol Immunother (2003) 52(11):680- 685.
24. Rubio V, Stuge TB, Singh N, Betts MR, Weber JS, Roederer M, Lee PP: Ex vivo identification, isolation and analysis of tumor-cytolytic T cells. Nat Med (2003) 9(11):1377-1382.
25. Arlen PM, Gulley JL, Parker C, Skarupa L, Pazdur M, Panicali D, Beetham P, Tsang KY, Grosenbach DW, Feldman J, Steinberg SM et al: A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer. Clin Cancer Res (2006) 12(4):1260-1269. •• This was the first clinical trial to demonstrate that the combination of immunotherapy and docetaxel in patients with metastatic prostate cancer did not suppress T-cell-specific immune responses. In addition, the hypothesis that patients first administered vaccine may have a more sustained response to subsequent chemotherapy was also suggested.
26. Cell Genesys: Cell Genesys halts VITAL-2 GVAX trial in advanced prostate cancer. Press Release (2008):August 27. http://phx. corporate-ir.net/phoenix.zhtml?c=98399&p=irol-newsArticle&ID=1191052 • An increased death rate in patients with metastatic CRPC in the vaccine and chemotherapy combination arm of the trial was observed; this trial may have an impact on future vaccine trial design.
27. Machiels JP, Reilly RT, Emens LA, Ercolini AM, Lei RY, Weintraub D, Okoye FI, Jaffee EM: Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice. Cancer Res (2001) 61(9):3689-3697.
28. Small EJ, Tchekmedyian NS, Rini BI, Fong L, Lowy I, Allison JP: A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer. Clin Cancer Res (2007) 13(6):1810-1815. • This pilot clinical trial demonstrated the safety of ipilimumab in patients with CRPC and established a preliminary toxicity profile.
29. Langer LF, Clay TM, Morse MA: Update on anti-CTLA-4 antibodies in clinical trials. Expert Opin Biol Ther (2007) 7(8): 1245-1256.
30. O'Mahony D, Morris JC, Quinn C, Gao W, Wilson WH, Gause B, Pittaluga S, Neelapu S, Brown M, Fleisher TA, Gulley JL et al: A pilot study of CTLA-4 blockade after cancer vaccine failure in patients with advanced malignancy. Clin Cancer Res (2007) 13(3):958-964.
31. Gulley JL, Dahut WL: Future directions in tumor immunotherapy: CTLA4 blockade. Nat Clin Pract Oncol (2007) 4(3):136-137.
32. Gerritsen W, van den Eertwegh AJ, de Gruijl T, van den Berg HP, Scheper RJ, Sacks N, Lowy I, Stankevich E, Hege K: Expanded phase I combination trial of GVAX immunotherapy for prostate cancer and ipilimumab in patients with metastatic hormone-refractory prostate cancer (mHPRC). J Clin Oncol (2008) 26(Suppl):Abs 5146.
33. Gulley J: Phase I trial of a targeted therapy with a PSA based vaccine and ipilimumab in patients with metastatic castration resistant prostate cancer (CRPC). National Cancer Institute, Bethesda, MD, USA (2008). www.mccm.nl/images/pp4%20james%20gulley.pdf
34. Marshall J, Gulley JL, Arlen PM, Beetham PK, Tsang KY, Slack R, Hodge JW, Doren S, Grosenbach DW, Hwang J, Fox E et al: A phase I study of sequential vaccinations with fowlpox-CEA(6D)-TRICOM (B7-1/ICAM-1/LFA-3) alone and sequentially with vaccinia-CEA(6D)-TRICOM, with and without GM-CSF, in patients with CEA-expressing carcinomas. J Clin Oncol (2004) 23(4):720-731.
35. Small EJ, Schellhammer PF, Higano CS, Redfern CH, Nemunaitis JJ, Valone FH, Verjee SS, Jones LA, Hershberg RM: Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol (2006) 24(19):3089-3094. •• This clinical trial failed to reach its primary endpoint of improved time to disease progression, but showed a significant overall survival benefit with sipuleucel-T. This result has important implications for future vaccine trials and strengthens the hypothesis that RECIST-based endpoints may not be appropriate for vaccine studies.
36. Sin JI, Hong SH, Park YJ, Park JB, Choi YS, Kim MS: Antitumor therapeutic effects of e7 subunit and DNA vaccines in an animal cervical cancer model: Antitumor efficacy of e7 therapeutic vaccines is dependent on tumor sizes, vaccine doses, and vaccine delivery routes. DNA Cell Biol (2006) 25(5):277-286.
37. Hoos A, Parmiani G, Hege K, Sznol M, Loibner H, Eggermont A, Urba W, Blumenstein B, Sacks N, Keilholz U, Nichol G et al: A clinical development paradigm for cancer vaccines and related biologics. J Immunother (2007) 30(1):1-15.
38. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: Moving beyond current vaccines. Nat Med (2004) 10(9):909-915.
39. Hodge JW, Chakraborty M, Kudo-Saito C, Garnett CT, Schlom J. Multiple costimulatory modalities enhance CTL avidity. J Immunol (2005) 174(10):5994-6004.
40. Oh S, Hodge JW, Ahlers JD, Burke DS, Schlom J, Berzofsky JA: Selective induction of high avidity CTL by altering the balance of signals from APC. J Immunol (2003) 170(5):2523-2530.
41. Kass E, Panicali DL, Mazzara G, Schlom J, Greiner JW. Granulocyte/macrophage-colony stimulating factor produced by recombinant avian poxviruses enriches the regional lymph nodes with antigen-presenting cells and acts as an immunoadjuvant. Cancer Res (2001) 61(1):206-214.
42. Borrello I, Pardoll D. GM-CSF-based cellular vaccines: A review of the clinical experience. Cytokine Growth Factor Rev (2002) 13(2):185-193.
43. Wang K, Gao X, Pang J, Liu X, Cai Y, Zhang Y, Zhou J, Zhan H: Dendritic cells transduced with a PSMA-encoding adenovirus and cocultured with autologous cytokine-induced lymphocytes induce a specific and strong immune response against prostate cancer cells. Urol Oncol (2008):doi:10.1016/j.urolonc.2007.09.003.
44. Sousa-Canavez JM, Canavez FC, Leite KR, Camara-Lopes LH: Therapeutic dendritic cell vaccine preparation using tumor RNA transfection: A promising approach for the treatment of prostate cancer. Genet Vaccines Ther (2008) 6:2.
45. Hildenbrand B, Sauer B, Kalis O, Stoll C, Freudenberg MA, Niedermann G, Giesler JM, Jüttner E, Peters JH, Häring B, Leo R et al: Immunotherapy of patients with hormone-refractory prostate carcinoma pre-treated with interferon-γ and vaccinated with autologous PSA-peptide loaded dendritic cells - a pilot study. Prostate (2007) 67(5):500-508.
46. Hobeika AC, Clay TM, Mosca PJ, Lyerly HK, Morse MA: Quantitating therapeutically relevant T-cell responses to cancer vaccines. Crit Rev Immunol (2001) 21(1-3):287-297.
47. Hodge JW, Abrams S, Schlom J, Kantor JA: Induction of antitumor immunity by recombinant vaccinia viruses expressing B7-1 or B7-2 costimulatory molecules. Cancer Res (1994) 54(21):5552-5555.
48. Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, Evdemon-Hogan M, Conejo-Garcia JR, Zhang L, Burow M, Zhu Y et al: Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med (2004) 10(9):942-949.
49. high regulatory T-cells in tumor-draining lymph nodes in patients with gastric cancer. J Surg Res (2005) 124(1):151-157.
50. Serafini P, De Santo C, Marigo I, Cingarlini S, Dolcetti L, Gallina G, Zanovello P, Bronte V: Derangement of immune responses by myeloid suppressor cells. Cancer Immunol Immunother (2004) 53(2):64-72.
51. Kusmartsev S, Gabrilovich DI: Immature myeloid cells and cancer-associated immune suppression. Cancer Immunol Immunother (2002) 51(6):293-298.
52. Schabowsky RH, Madireddi S, Sharma R, Yolcu ES, Shirwan H: Targeting CD4+CD25+FoxP3+ regulatory T-cells for the augmentation of cancer immunotherapy. Curr Opin Investig Drugs (2007) 8(12):1002- 1008.
53. Motoyoshi Y, Kaminoda K, Saitoh O, Hamasaki K, Nakao K, Ishii N, Nagayama Y, Eguchi K: Different mechanisms for anti-tumor effects of low- and high-dose cyclophosphamide. Oncol Rep (2006) 16(1):141-146.
54. Lutsiak ME, Semnani RT, De Pascalis R, Kashmiri SV, Schlom J, Sabzevari H: Inhibition of CD4+25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood (2005) 105(7):2862-2868.
55. Morse MA, Hobeika AC, Osada T, Serra D, Niedzwiecki D, Lyerly HK, Clay TM: Depletion of human regulatory T cells specifically enhances antigen-specific immune responses to cancer vaccines. Blood (2008) 112(3):610-618.
56. Litzinger MT, Fernando R, Curiel TJ, Grosenbach DW, Schlom J, Palena C: IL-2 immunotoxin denileukin diftitox reduces regulatory T cells and enhances vaccine-mediated T-cell immunity. Blood (2007) 110(9):3192- 3201.
57. Cavacini LA, Duval M, Eder JP, Posner MR: Evidence of determinant spreading in the antibody responses to prostate cell surface antigens in patients immunized with prostate-specific antigen. Clin Cancer Res (2002) 8(2):368-373.